Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants

Alfredo Marzano, Pietro Lampertico, Vincenzo Mazzaferro, Silvia Carenzi, Mauro Vigano, Raffaele Romito, Andrea Pulvirenti, Alessandro Franchello, Massimo Colombo, Mauro Salizzoni, Mario Rizzetto

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The combination of lamivudine and hepatitis B immunoglobulin (HBIG) reduces the risk of hepatitis B virus (HBV) recurrence after liver transplantation (LI). However, the efficacy of this strategy and the need for combined therapy with adelovir dipivoxil (ADV) in patients who select lamivudine-resistant strains (YMDD) before surgery is still unknown. Twenty-two patients treated with lamivudine (LAM) who underwent LT after YMDD-mutant selection were studied. In 13 patients, YMDD mutants were associated with an HBV DNA breakthrough greater than 5 log10 (group A: phenotypic resistance), and 11 were treated with ADV to decrease viral load before LT. In the remaining 9 patients who did not experience the viral breakthrough, YMDD mutants were detected only retrospectively in sera stored at the time of LT (group B: genotypic resistance). During 35 months of post-LT follow-up, none of the 11 patients of group A treated with ADV before and after surgery (in addition to HBIG and LAM) had HBV recurrence, and neither did any of the 7 subjects of group B treated with LAM before and after transplantation (in addition to HBIG). HBV recurred in 2 patients of group A (untreated with ADV before surgery and transplanted with an HBV DNA exceeding 5 log10) and in 2 subjects of group B (who spontaneously stopped HBIG after surgery). In carriers of YMDD mutants, the risk of post-LT HBV recurrence is low, provided that preemptive and prophylactic ADV (in addition to LAM and HBIG) treatment is used in highly viremic patients and prophylactic LAM (or ADV) and HBIG therapy is continued in low viremic patients.

Original languageEnglish
Pages (from-to)532-538
Number of pages7
JournalLiver Transplantation
Volume11
Issue number5
DOIs
Publication statusPublished - May 2005

Fingerprint

Lamivudine
Hepatitis B virus
Liver Transplantation
Hepatitis B
Recurrence
Immunoglobulins
Passive Immunization
DNA
Viral Load
Transplantation
Therapeutics
Serum

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. / Marzano, Alfredo; Lampertico, Pietro; Mazzaferro, Vincenzo; Carenzi, Silvia; Vigano, Mauro; Romito, Raffaele; Pulvirenti, Andrea; Franchello, Alessandro; Colombo, Massimo; Salizzoni, Mauro; Rizzetto, Mario.

In: Liver Transplantation, Vol. 11, No. 5, 05.2005, p. 532-538.

Research output: Contribution to journalArticle

Marzano, A, Lampertico, P, Mazzaferro, V, Carenzi, S, Vigano, M, Romito, R, Pulvirenti, A, Franchello, A, Colombo, M, Salizzoni, M & Rizzetto, M 2005, 'Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants', Liver Transplantation, vol. 11, no. 5, pp. 532-538. https://doi.org/10.1002/lt.20393
Marzano, Alfredo ; Lampertico, Pietro ; Mazzaferro, Vincenzo ; Carenzi, Silvia ; Vigano, Mauro ; Romito, Raffaele ; Pulvirenti, Andrea ; Franchello, Alessandro ; Colombo, Massimo ; Salizzoni, Mauro ; Rizzetto, Mario. / Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. In: Liver Transplantation. 2005 ; Vol. 11, No. 5. pp. 532-538.
@article{d44f5f0149f3436da4645541d39dfbfa,
title = "Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants",
abstract = "The combination of lamivudine and hepatitis B immunoglobulin (HBIG) reduces the risk of hepatitis B virus (HBV) recurrence after liver transplantation (LI). However, the efficacy of this strategy and the need for combined therapy with adelovir dipivoxil (ADV) in patients who select lamivudine-resistant strains (YMDD) before surgery is still unknown. Twenty-two patients treated with lamivudine (LAM) who underwent LT after YMDD-mutant selection were studied. In 13 patients, YMDD mutants were associated with an HBV DNA breakthrough greater than 5 log10 (group A: phenotypic resistance), and 11 were treated with ADV to decrease viral load before LT. In the remaining 9 patients who did not experience the viral breakthrough, YMDD mutants were detected only retrospectively in sera stored at the time of LT (group B: genotypic resistance). During 35 months of post-LT follow-up, none of the 11 patients of group A treated with ADV before and after surgery (in addition to HBIG and LAM) had HBV recurrence, and neither did any of the 7 subjects of group B treated with LAM before and after transplantation (in addition to HBIG). HBV recurred in 2 patients of group A (untreated with ADV before surgery and transplanted with an HBV DNA exceeding 5 log10) and in 2 subjects of group B (who spontaneously stopped HBIG after surgery). In carriers of YMDD mutants, the risk of post-LT HBV recurrence is low, provided that preemptive and prophylactic ADV (in addition to LAM and HBIG) treatment is used in highly viremic patients and prophylactic LAM (or ADV) and HBIG therapy is continued in low viremic patients.",
author = "Alfredo Marzano and Pietro Lampertico and Vincenzo Mazzaferro and Silvia Carenzi and Mauro Vigano and Raffaele Romito and Andrea Pulvirenti and Alessandro Franchello and Massimo Colombo and Mauro Salizzoni and Mario Rizzetto",
year = "2005",
month = "5",
doi = "10.1002/lt.20393",
language = "English",
volume = "11",
pages = "532--538",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants

AU - Marzano, Alfredo

AU - Lampertico, Pietro

AU - Mazzaferro, Vincenzo

AU - Carenzi, Silvia

AU - Vigano, Mauro

AU - Romito, Raffaele

AU - Pulvirenti, Andrea

AU - Franchello, Alessandro

AU - Colombo, Massimo

AU - Salizzoni, Mauro

AU - Rizzetto, Mario

PY - 2005/5

Y1 - 2005/5

N2 - The combination of lamivudine and hepatitis B immunoglobulin (HBIG) reduces the risk of hepatitis B virus (HBV) recurrence after liver transplantation (LI). However, the efficacy of this strategy and the need for combined therapy with adelovir dipivoxil (ADV) in patients who select lamivudine-resistant strains (YMDD) before surgery is still unknown. Twenty-two patients treated with lamivudine (LAM) who underwent LT after YMDD-mutant selection were studied. In 13 patients, YMDD mutants were associated with an HBV DNA breakthrough greater than 5 log10 (group A: phenotypic resistance), and 11 were treated with ADV to decrease viral load before LT. In the remaining 9 patients who did not experience the viral breakthrough, YMDD mutants were detected only retrospectively in sera stored at the time of LT (group B: genotypic resistance). During 35 months of post-LT follow-up, none of the 11 patients of group A treated with ADV before and after surgery (in addition to HBIG and LAM) had HBV recurrence, and neither did any of the 7 subjects of group B treated with LAM before and after transplantation (in addition to HBIG). HBV recurred in 2 patients of group A (untreated with ADV before surgery and transplanted with an HBV DNA exceeding 5 log10) and in 2 subjects of group B (who spontaneously stopped HBIG after surgery). In carriers of YMDD mutants, the risk of post-LT HBV recurrence is low, provided that preemptive and prophylactic ADV (in addition to LAM and HBIG) treatment is used in highly viremic patients and prophylactic LAM (or ADV) and HBIG therapy is continued in low viremic patients.

AB - The combination of lamivudine and hepatitis B immunoglobulin (HBIG) reduces the risk of hepatitis B virus (HBV) recurrence after liver transplantation (LI). However, the efficacy of this strategy and the need for combined therapy with adelovir dipivoxil (ADV) in patients who select lamivudine-resistant strains (YMDD) before surgery is still unknown. Twenty-two patients treated with lamivudine (LAM) who underwent LT after YMDD-mutant selection were studied. In 13 patients, YMDD mutants were associated with an HBV DNA breakthrough greater than 5 log10 (group A: phenotypic resistance), and 11 were treated with ADV to decrease viral load before LT. In the remaining 9 patients who did not experience the viral breakthrough, YMDD mutants were detected only retrospectively in sera stored at the time of LT (group B: genotypic resistance). During 35 months of post-LT follow-up, none of the 11 patients of group A treated with ADV before and after surgery (in addition to HBIG and LAM) had HBV recurrence, and neither did any of the 7 subjects of group B treated with LAM before and after transplantation (in addition to HBIG). HBV recurred in 2 patients of group A (untreated with ADV before surgery and transplanted with an HBV DNA exceeding 5 log10) and in 2 subjects of group B (who spontaneously stopped HBIG after surgery). In carriers of YMDD mutants, the risk of post-LT HBV recurrence is low, provided that preemptive and prophylactic ADV (in addition to LAM and HBIG) treatment is used in highly viremic patients and prophylactic LAM (or ADV) and HBIG therapy is continued in low viremic patients.

UR - http://www.scopus.com/inward/record.url?scp=21044434308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21044434308&partnerID=8YFLogxK

U2 - 10.1002/lt.20393

DO - 10.1002/lt.20393

M3 - Article

VL - 11

SP - 532

EP - 538

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 5

ER -